The Pharmacological Approach to Oncologic Patients with Acute Coronary Syndrome
Juri Radmilovic, Alessandro Di Vilio, Antonello D’Andrea, Fabio Pastore, Alberto Forni, Alfonso Desiderio, Massimo Ragni, Gaetano Quaranta, Giovanni Cimmino, Vincenzo Russo, Marino Scherillo, Paolo Golino
Abstract
Among acute coronary syndrome (ACS) patients, 15% have concomitant cancer, especially in the first 6 months after their diagnosis, as well as in advanced metastatic stages. Lung, gastric, and pancreatic cancers are the most frequent malignancies associated with ACS. Chemotherapy and radiotherapy exert prothrombotic, vasospastic, and proinflammatory actions. The management of cancer patients with ACS is quite challenging: percutaneous revascularization is often underused, and antiplatelet and anticoagulant pharmacological therapy should be individually tailored to the thrombotic risk and to the bleeding complications. Sometimes oncological patients also show different degrees of thrombocytopenia, which further complicates the pharmacological strategies. The aim of this review is to summarize the current evidence regarding the treatment of ACS in cancer patients and to suggest the optimal management and therapy to reduce the risk of adverse coronary events after ACS in this high-risk population.